Skip to main content

Advertisement

SpringerLink
Log in

The Intersection of Prostate Cancer and Hypertension: a Call to Action

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

With improvements in treatment and survival from prostate cancer, comorbid cardiac conditions will significantly impact overall morbidity and mortality from prostate cancer. Hypertension is a well-established cardiovascular risk factor that increases the risk of heart failure, myocardial infarction, and stroke. Therapies used in the treatment of prostate cancer, including GnRH agonists, GnRH antagonists, enzalutamide, abiraterone, and others, can directly or indirectly increase the risk of hypertension. In this paper, we review the evidence available on the incidence and mechanism of hypertension in prostate cancer patients. In addition, we provide recommendations on the assessment, treatment, and future directions for hypertension management in the prostate cancer population. We propose an individualized goal for blood pressure in prostate cancer patients, balancing the target goal of 130/80 mmHg with common comorbidities of frailty, orthostatic symptoms, and imbalance in this population. The presence of additional comorbidities (myocardial infarction, heart failure, renal disease, diabetes) can assist in preference of anti-hypertensive drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

  1. Quaresma M, Coleman MP, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet. 2015;385(9974):1206–18.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.

    Article  PubMed  Google Scholar 

  3. Guha A, Armanious M, Fradley MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019;29(1):29–39.

    Article  CAS  PubMed  Google Scholar 

  4. Neves KB, Montezano AC, Lang NN, Touyz RM. Vascular toxicity associated with anti-angiogenic drugs. Clin Sci (Lond). 2020;134(18):2503–20.

    Article  CAS  PubMed  Google Scholar 

  5. van Dorst DCH, Dobbin SJH, Neves KB, Herrmann J, Herrmann SM, Versmissen J, et al. Hypertension and prohypertensive antineoplastic therapies in cancer patients. Circ Res. 2021;128(7):1040–61.

    Article  PubMed  PubMed Central  Google Scholar 

  6. O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51.

    Article  PubMed  Google Scholar 

  7. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.

    Article  CAS  PubMed  Google Scholar 

  8. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 125 million people. Lancet. 2014;383(9932):1899–911.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–492.

    Article  PubMed  Google Scholar 

  10. Forrester SJ, Dolmatova EV, Griendling KK. An acceleration in hypertension-related mortality for middle-aged and older Americans, 1999–2016: An observational study. PLoS ONE. 2020;15(1):e0225207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Fullerton HJ, Stratton K, Mueller S, Leisenring WW, Armstrong GT, Weathers RE, et al. Recurrent stroke in childhood cancer survivors. Neurology. 2015;85(12):1056–64.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  14. Prostate Cancer Statistics | CDC.Center for Disease Control and Prevention. 2022 [cited 2023. Available from: https://www.cdc.gov/cancer/prostate/statistics/index.htm. Accessed 30 Dec 2022.

  15. Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, et al. Epidemiology and prevention of prostate cancer. Eur Urol Oncol. 2021;4(6):877–92.

    Article  PubMed  Google Scholar 

  16. Liang Z, Xie B, Li J, Wang X, Wang S, Meng S, et al. Hypertension and risk of prostate cancer: a systematic review and meta-analysis. Sci Rep. 2016;6:31358.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Katsi V, Magkas N, Georgiopoulos G, Athanasiadi E, Virdis A, Masi S, et al. Arterial hypertension in patients under antineoplastic therapy: a systematic review. J Hypertens. 2019;37(5):884–901.

    Article  CAS  PubMed  Google Scholar 

  18. Gudsoorkar P, Ruf R, Adnani H, Safdar K, Sparks MA. Onco-hypertension: An Emerging Specialty. Adv Chronic Kidney Dis. 2021;28(5):477–89 e1.

  19. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

    Article  CAS  PubMed  Google Scholar 

  24. Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lester JF, Mason MD. Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf. 2015;7:129–38.

    PubMed  PubMed Central  Google Scholar 

  26. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144(16):1295–307.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ortmann O, Weiss JM, Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1–7.

    Article  PubMed  Google Scholar 

  28. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2):195–201.

    Article  CAS  PubMed  Google Scholar 

  29. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.

    Article  CAS  PubMed  Google Scholar 

  30. Tayek JA, Heber D, Byerley LO, Steiner B, Rajfer J, Swerdloff RS. Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism. 1990;39(12):1314–9.

    Article  CAS  PubMed  Google Scholar 

  31. Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective analysis of patients with prostate cancer initiating GnRH agonists/antagonists therapy using a german claims database: epidemiological and patient outcomes. Front Oncol. 2018;8:543.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Perrone V, DegliEsposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126(1):9–10.

    Article  CAS  PubMed  Google Scholar 

  34. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96.

    Article  CAS  PubMed  Google Scholar 

  35. Patel S. Mechanism and predictors of cardiotoxicity after prostate cancer treatment: a parallel cohort and randomized trial comparing radiation alone, radiation plus leuprolide, and radiation plusrelugolix 2022 [Available from: https://clinicaltrials.gov/ct2/show/NCT05320406. Accessed 30 Dec 2022.

  36. GmbH MS.Relugolix versus leuprolide in patients with prostate cancer: a randomized, open-label study to assess major adverse cardiovascular events (REPLACE-CV) 2022 [Available from: https://www.clinicaltrials.gov/ct2/show/NCT05605964. Accessed 30 Dec 2022.

  37. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis–immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003;178(3):373–80.

    Article  CAS  PubMed  Google Scholar 

  38. Challa AA, Calaway AC, Cullen J, Garcia J, Desai N, Weintraub NL, et al. Cardiovascular toxicities of androgen deprivation therapy. Curr Treat Options Oncol. 2021;22(6):47.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3 Suppl 3(Suppl 3):S10–4.

  40. Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35(5):183–91.

    Article  CAS  PubMed  Google Scholar 

  41. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Res. 2009;50 Suppl(Suppl):S352–7.

  42. AdministrationUFaD. FDA approves enzalutamide for metastatic castration-sensitive prostate cancer 2019 [Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer. Accessed 20 Dec 2022.

  43. Zhu X, Wu S. Increased risk of hypertension with enzalutamide in prostate cancer: a meta-analysis. Cancer Invest. 2019;37(9):478–88.

    Article  PubMed  Google Scholar 

  44. Enzalutamide [package insert].Northbrook, IL; Astellas Pharma US, Inc; 2012. .

  45. Zhu X, Wu S. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review. Clin Hypertens. 2022;28(1):14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Scragg JL, Dallas ML, Peers C. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium. 2007;42(1):11–5.

    Article  CAS  PubMed  Google Scholar 

  47. Zhu X, Wu S. Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. Clin Hypertens. 2019;25:5.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645–53.

    Article  PubMed  Google Scholar 

  49. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol. 2012;27(7):1059–66.

    Article  PubMed  Google Scholar 

  50. De Wachter E, Vanbesien J, De Schutter I, Malfroot A, De Schepper J. Rapidly developing Cushing syndrome in a 4-year-old patient during combined treatment with itraconazole and inhaled budesonide. Eur J Pediatr. 2003;162(7–8):488–9.

    Article  PubMed  Google Scholar 

  51. Fallo F, Fanelli G, Cipolla A, Betterle C, Boscaro M, Sonino N. 24-hour blood pressure profile in Addison’s disease. Am J Hypertens. 1994;7(12):1105–9.

    Article  CAS  PubMed  Google Scholar 

  52. Piovesan A, Panarelli M, Terzolo M, Osella G, Matrella C, Paccotti P, et al. 24-hour profiles of blood pressure and heart rate in Cushing’s syndrome: relationship between cortisol and cardiovascular rhythmicities. Chronobiol Int. 1990;7(3):263–5.

    Article  CAS  PubMed  Google Scholar 

  53. Imai Y, Abe K, Sasaki S, Minami N, Munakata M, Nihei M, et al. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. J Hypertens. 1989;7(2):113–20.

    Article  CAS  PubMed  Google Scholar 

  54. Aras-Lopez R, Xavier FE, Ferrer M, Balfagon G. Dexamethasone decreases neuronal nitric oxide release in mesenteric arteries from hypertensive rats through decreased protein kinase C activation. Clin Sci (Lond). 2009;117(8):305–12.

    Article  CAS  PubMed  Google Scholar 

  55. Birkenhager AM, van den Meiracker AH. Causes and consequences of a non-dipping blood pressure profile. Neth J Med. 2007;65(4):127–31.

    CAS  PubMed  Google Scholar 

  56. Hjortkjaer HO, Persson F, Theilade S, Winther SA, Tofte N, Ahluwalia TS, et al. Non-dipping and higher nocturnal blood pressure are associated with risk of mortality and development of kidney disease in type 1 diabetes. J Diabetes Complications. 2022;36(9):108270.

    Article  PubMed  Google Scholar 

  57. Ivy JR, Jones NK, Costello HM, Mansley MK, Peltz TS, Flatman PW, et al. Glucocorticoid receptor activation stimulates the sodium-chloride cotransporter and influences the diurnal rhythm of its phosphorylation. Am J Physiol Renal Physiol. 2019;317(6):F1536–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Ivy JR, Oosthuyzen W, Peltz TS, Howarth AR, Hunter RW, Dhaun N, et al. Glucocorticoids induce nondipping blood pressure by activating the thiazide-sensitive cotransporter. Hypertension. 2016;67(5):1029–37.

    Article  CAS  PubMed  Google Scholar 

  59. Hermida RC, Calvo C, Ayala DE, Fernandez JR, Covelo M, Mojon A, et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens. 2005;23(10):1913–22.

    Article  CAS  PubMed  Google Scholar 

  60. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  61. Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–7.

    Article  PubMed  Google Scholar 

  62. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–55.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;392(10145):382–3.

    Article  PubMed  Google Scholar 

  67. Ana Oaknin LG, Anna Tinker, Renaud Sabatier, Jubilee Brown, Cara Mathews, Valentina Boni, Vanessa Samouelian, David O’Malley, Andrea Jewell, Susana Banerjee, Grace Antony, Jennifer Veneris, Bhavana Pothuri. Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post hoc analysis from the GARNET trial. Annual Meeting on Women’s Cancer; Phoenix, AZ2022.

  68. Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol. 2018;34(8):1059–68.

    Article  PubMed  Google Scholar 

  69. Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors-associated cardiotoxicity. Cancers (Basel). 2022;14(5):1145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Ji C, Roy MD, Golas J, Vitsky A, Ram S, Kumpf SW, et al. Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors. Clin Cancer Res. 2019;25(15):4735–48.

    Article  CAS  PubMed  Google Scholar 

  72. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  73. Docetaxel [patient information leaflet]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; 2004.

  74. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006;33(1):2–14.

    Article  CAS  PubMed  Google Scholar 

  75. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112(6):479–86.

    Article  PubMed  Google Scholar 

  76. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.

    Article  PubMed  Google Scholar 

  77. Cushman WC, Whelton PK, Fine LJ, Wright JT Jr, Reboussin DM, Johnson KC, et al. SPRINT trial results: latest news in hypertension management. Hypertension. 2016;67(2):263–5.

    Article  CAS  PubMed  Google Scholar 

  78. Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.

    Article  CAS  PubMed  Google Scholar 

  79. Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  Google Scholar 

  80. Boutcher YN, Boutcher SH. Exercise intensity and hypertension: what’s new? J Hum Hypertens. 2017;31(3):157–64.

    Article  CAS  PubMed  Google Scholar 

  81. Idorn M, Thor SP. Exercise and cancer: from “healthy” to “therapeutic”? Cancer Immunol Immunother. 2017;66(5):667–71.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr., das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71(20):2281–90.

  83. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Laurent S. Antihypertensive drugs. Pharmacol Res. 2017;124:116–25.

    Article  CAS  PubMed  Google Scholar 

  85. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Kenk M, Gregoire JC, Cote MA, Connelly KA, Davis MK, Dresser G, et al. Optimizing screening and management of cardiovascular health in prostate cancer: a review. Can Urol Assoc J. 2020;14(9):E458–64.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Mandawat A, Williams AE, Francis SA. Cardio-oncology: the role of big data. Heart Fail Clin. 2017;13(2):403–8.

    Article  PubMed  Google Scholar 

  88. Liang Z, He Y, Hu X. Cardio-oncology: mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci. 2022;23(18):10617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Emory University School of Medicine, Atlanta, GA, USA

    Elena Dolmatova MD, Nida Waheed MD, Brian Michael Olson PhD, Sagar A. Patel MD, MPH & Anant Mandawat MD

  2. Cardio-Oncology Center of Excellence, Emory University, 1365B Clifton Rd NE Suite 4000, Atlanta, GA, 30322, USA

    Anant Mandawat MD

Authors
  1. Elena Dolmatova MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nida Waheed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brian Michael Olson PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sagar A. Patel MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anant Mandawat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anant Mandawat MD.

Ethics declarations

Conflict of Interest

Elena Dolmatova declares that she has no conflict of interest. Nida Waheed declares that she has no conflict of interest. Brian Michael Olson declares that she has no conflict of interest. Sagar Patel declares that she has no conflict of interest. Anant Mandawat declares that she has no conflict of interest.

AM, BMO, and SP report significant research support from the Prostate Cancer Foundation, Pfizer, and Myovant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Elena Dolmatova and Nida Waheed are co-first authors.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolmatova, E., Waheed, N., Olson, B.M. et al. The Intersection of Prostate Cancer and Hypertension: a Call to Action. Curr. Treat. Options in Oncol. 24, 892–905 (2023). https://doi.org/10.1007/s11864-023-01094-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01094-z

Keywords

Search

Navigation